Incidence of New-onset and Flare of Preexisting Psoriasis During Rituximab Therapy for Rheumatoid Arthritis: Data from the French AIR Registry
Authors:
- Florence Canoui-PoitrineFCFlorence Canoui-Poitrine
- Jacques-Eric GottenbergJGJacques-Eric Gottenberg
- Andra Economu-DuboscAEAndra Economu-Dubosc
- Fatiha MedkourFMFatiha Medkour
- Xavier ChevalierXCXavier Chevalier
- Sylvie Bastuji-GarinSBSylvie Bastuji-Garin
- Hervé LE LouëtHLHervé LE Louët
- Valérie FarrenqVFValérie Farrenq
- Pascal ClaudepierrePCPascal Claudepierre
Open Access
- 15 April 2012
- journal article
- research article
- Published by The Journal of Rheumatology in The Journal of Rheumatology
- Vol. 39 (5) , 893-898
Abstract
Objective.: Psoriasis could be a paradoxical reaction to tumor necrosis factor-α antagonist therapy and it has been reported with rituximab therapy. Our objective was to assess the rates of new-onset and flare of preexisting psoriasis in patients taking rituximab for rheumatoid arthritis (RA).Methods.: The nationwide multicenter prospective AutoImmunity and Rituximab (AIR) registry was set up in 2006 by the French Society for Rheumatology to collect data on patients taking rituximab for joint diseases. We identified patients with RA in the registry who had psoriasis listed as an adverse drug reaction, and we obtained additional information from their physicians if needed. We computed the incidence rates of new-onset and flare of preexisting psoriasis according to the rituximab exposure time.Results.: Among the 1927 patients in the registry with RA, 2 had new-onset and 5 had flare of preexisting psoriasis after a median followup of 39.2 weeks. Incidence rates were 1.04/1000 person-years (95% CI 0.13 to 3.8) for new-onset psoriasis and 2.6/1000 person-years (95% CI 0.84 to 6.1) for flare of preexisting psoriasis. Rituximab rechallenge in the 2 new-onset cases and in 2 flare cases was not followed by recurrence or exacerbation of psoriasis. Two of the 5 flare cases developed after discontinuation of methotrexate.Conclusion.: Despite the small number of cases observed, leading to wide CI, the incidence rates in our study do not support a causative role of rituximab therapy in new-onset or flare of preexisting psoriasis in patients with RA.Keywords
This publication has 22 references indexed in Scilit:
- Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor α therapy: results from the British Society for Rheumatology Biologics RegisterAnnals of the Rheumatic Diseases, 2009
- Granuloma annulare induced by anti-tumour necrosis factor therapyAnnals of the Rheumatic Diseases, 2008
- Flare and change of psoriasis morphology during the course of treatment with tumour necrosis factor blockersClinical and Experimental Dermatology, 2007
- A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agentsAnnals of the Rheumatic Diseases, 2006
- The evaluation of psoriasis therapy with biologics leads to a revision of the current view of the pathogenesis of this disorderExpert Opinion on Therapeutic Targets, 2006
- Flambée d'un Psoriasis cutané sous Adalimumab puis sous Etanercept chez une patiente souffrant de Polyarthrite Rhumatoïde et d'une Maladie de CrohnRevue du Rhumatisme, 2006
- Anti-Tumor Necrosis Factor Alpha-Induced Psoriasiform Eruptions: Three Further Cases and Current OverviewDermatology, 2006
- New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor α antagonistsAnnals of the Rheumatic Diseases, 2006
- Psoriasis induced by anti–tumor necrosis factor therapy: A paradoxical adverse reactionArthritis & Rheumatism, 2005
- Adverse Skin Reactions to Anti-TNF-Alpha Monoclonal Antibody TherapyDermatology, 2003